Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TTNP
TTNP logo

TTNP Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
5.07M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
31.25M
EV/OCF(TTM)
--
P/S(TTM)
--
Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
Show More

Events Timeline

(ET)
2025-06-03
08:48:58
Titan announces filing of registration statement for proposed combination
select
2024-11-27 (ET)
2024-11-27
15:07:30
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
select

News

Benzinga
8.5
2025-08-27Benzinga
Titan Pharmaceuticals Shares Jump 23% in After-Hours Trading Following Stockholder Endorsement of Three-Way Merger
  • Stock Surge After Merger Approval: Titan Pharmaceuticals, Inc. saw its stock price rise 23% in after-hours trading to $6.15 following the approval of a major business combination by stockholders.

  • Merger Details: Stockholders overwhelmingly approved a three-way merger with Black Titan Corporation and TalenTec Sdn. Bhd., with 730,383 votes in favor and only 1,860 against.

  • Market Impact: The company's stock has experienced significant volatility over the past year, with a market capitalization of $6.70 million and an average daily trading volume of 39,920 shares.

  • Remaining Conditions: The merger is still subject to additional closing conditions, including Nasdaq listing approval for Black Titan ordinary shares, as outlined in the original agreement dated August 19, 2024.

Globenewswire
7.0
2025-08-06Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, HLVX, BSGM, TTNP on Behalf of Shareholders
  • Investor Rights Investigation: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales and mergers involving Steelcase Inc., HilleVax, BioSig Technologies, and Titan Pharmaceuticals, urging shareholders to explore their legal rights.

  • Legal Support Offered: The firm offers contingent fee-based legal representation for affected shareholders, emphasizing that they will not incur out-of-pocket expenses for legal fees or costs while seeking increased consideration and disclosures in the proposed transactions.

Globenewswire
7.0
2025-07-30Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, VBTX, TTNP on Behalf of Shareholders July 31, 2025
  • Investigation of Companies: Halper Sadeh LLC is investigating iTeos Therapeutics, Veritex Holdings, and Titan Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed sales and mergers.

  • Shareholder Rights: The firm encourages shareholders from these companies to contact them for free consultations regarding their legal rights and options, emphasizing that they operate on a contingency fee basis.

PRnewswire
7.0
2025-07-29PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, SPTN, TTNP on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating Couchbase, SpartanNash, and Titan Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales and mergers.

  • Legal Support for Shareholders: The firm offers free consultations to shareholders regarding their legal rights and options, potentially seeking increased compensation or disclosures on behalf of the affected investors.

Globenewswire
8.5
2025-07-29Globenewswire
URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)
  • Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm for recovering millions for shareholders and is currently investigating Titan Pharmaceuticals' proposed merger with BSKE Ltd.

  • Shareholder Vote Information: Titan Pharmaceuticals shareholders are encouraged to participate in the upcoming vote on August 26, 2025, regarding the merger, with no cost or obligation for those seeking more information.

Globenewswire
7.0
2025-07-26Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating potential securities law violations and breaches of fiduciary duties related to mergers involving Carisma Therapeutics, Enzo Biochem, Hudson Global, and Titan Pharmaceuticals, encouraging shareholders to explore their legal rights.

  • Legal Support for Shareholders: The firm offers contingent fee-based legal services, meaning shareholders will not incur out-of-pocket expenses, and they are urged to contact the firm for free consultations regarding their options.

Valuation Metrics

The current forward P/E ratio for Titan Pharmaceuticals Inc (TTNP.O) is -0.49, compared to its 5-year average forward P/E of -0.86. For a more detailed relative valuation and DCF analysis to assess Titan Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.86
Current PE
-0.49
Overvalued PE
-0.35
Undervalued PE
-1.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.02
Undervalued EV/EBITDA
-0.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
45.69
Current PS
0.47
Overvalued PS
124.56
Undervalued PS
-33.19

Financials

AI Analysis
Annual
Quarterly

Whales Holding TTNP

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Titan Pharmaceuticals Inc (TTNP) stock price today?

The current price of TTNP is 0 USD — it has increased 0

What is Titan Pharmaceuticals Inc (TTNP)'s business?

Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.

What is the price predicton of TTNP Stock?

Wall Street analysts forecast TTNP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TTNP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Titan Pharmaceuticals Inc (TTNP)'s revenue for the last quarter?

Titan Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Titan Pharmaceuticals Inc (TTNP)'s earnings per share (EPS) for the last quarter?

Titan Pharmaceuticals Inc. EPS for the last quarter amounts to -0.65 USD, decreased -71.62

How many employees does Titan Pharmaceuticals Inc (TTNP). have?

Titan Pharmaceuticals Inc (TTNP) has 4 emplpoyees as of April 03 2026.

What is Titan Pharmaceuticals Inc (TTNP) market cap?

Today TTNP has the market capitalization of 5.07M USD.